Skip to main content

Market Overview

Pfizer's Tick-Borne Encephalitis Vaccine Gets Priority Review Tag In US

Share:
  • The FDA has accepted Pfizer Inc's (NYSE: PFE) marketing application seeking approval for TicoVac under priority review status. TicoVac is the tick-borne encephalitis (TBE) vaccine for active immunization in individuals aged one and older.
  • The anticipated action date is expected for August 2021.
  • TBE is a viral infection of the brain and spine, transmitted to humans through the bite of an infected tick.
  • The company's TBE vaccine is already marketed in Europe under the brand names TicoVac and FSME-Immun.
  • Price Action: PFE is up 0.12% at $33.95 in premarket trading on the last check Wednesday.
 

Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: tick-borne encephalitisBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com